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Abstract
Mutations in the all-trans retinoic acid (ATRA)-targeted ligand binding domain
of PML-RARα (PRα/LBD<sup>+</sup>) have been implicated in the passive
selection of ATRA-resistant acute promyelocytic leukemia clones leading to
disease relapse.Among 45 relapse patients from the ATRA/chemotherapy arm of
intergroup protocol C9710, 18 patients harbored PRα/LBD<sup>+</sup> (40%),
7 of whom (39%) relapsed Off-ATRA selection pressure, suggesting a possible
active role of PRα/LBD<sup>+</sup>. Of 41 relapse patients coanalyzed,
15 (37%) had FMS-related tyrosine kinase 3 internal tandem duplication
mutations (FLT3-ITD<sup>+</sup>), which were differentially associated with
PRα/LBD<sup>+</sup> depending on ATRA treatment status at relapse:
positively, On-ATRA; negatively, Off-ATRA. Thirteen of 21 patients (62%) had
additional chromosome abnormalities (ACAs); all coanalyzed PRα/LBD mutant
patients who relapsed off-ATRA (n = 5) had associated ACA. After relapse Off-
ATRA, ACA and FLT3-ITD<sup>+...
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Mutations in the all-trans retinoic acid
(ATRA)–targeted ligand binding domain
of PML-RAR (PR/LBD) have been im-
plicated in the passive selection of ATRA-
resistant acute promyelocytic leukemia
clones leading to disease relapse. Among
45 relapse patients from the ATRA/chemo-
therapy arm of intergroup protocol C9710,
18 patients harbored PR/LBD (40%),
7 of whom (39%) relapsed Off-ATRA selec-
tion pressure, suggesting a possible ac-
tive role of PR/LBD. Of 41 relapse pa-
tients coanalyzed, 15 (37%) had FMS-
related tyrosine kinase 3 internal tandem
duplication mutations (FLT3-ITD), which
were differentially associated with PR/
LBD depending on ATRA treatment sta-
tus at relapse: positively, On-ATRA; nega-
tively, Off-ATRA. Thirteen of 21 patients
(62%) had additional chromosome abnor-
malities (ACAs); all coanalyzed PR/LBD
mutant patients who relapsed off-ATRA
(n  5) had associated ACA. After relapse
Off-ATRA, ACA and FLT3-ITD were nega-
tively associated and were oppositely as-
sociated with presenting white blood
count and PML-RAR type: ACA, low,
L-isoform; FLT3-ITD, high, S-isoform.
These exploratory results suggest that
differing PR/LBD activities may inter-
act with FLT3-ITD or ACA, that FLT3-
ITD and ACA are associated with differ-
ent intrinsic disease progression
pathways manifest at relapse Off-ATRA,
and that these different pathways may be
short-circuited by ATRA-selectable de-
fects at relapse On-ATRA. ACA and cer-
tain PR/LBD were also associated with
reduced postrelapse survival. (Blood.
2012;120(10):2098-2108)
Introduction
Acute promyelocytic leukemia (APL) is initiated by formation of
the PML-RAR fusion gene, which is cytogenetically identifiable
by at t(15;17) in  90% of cases.1,2 Depending on which of
3 breakpoint cluster regions (bcr’s) in the PML gene on chromo-
some 15 is transected, 1 of 3 possible PML-RAR transcript types
is formed by joining to a single bcr in the RAR gene on
chromosome 17: the long (L), variable (V), or short (S)–isoform,
which is invariant in each APL case.3 At diagnosis, 2 other genetic
abnormalities are frequently associated with APL, mutations of the
FMS-related tyrosine kinase 3 (FLT3) gene,4 and chromosomal
abnormalities in addition to the t(15;17).5 Two types of FLT3
mutations occur that constitutively activate the molecule’s receptor
tyrosine kinase: internal tandem duplication mutations (FLT3-
ITD) in the juxtamembrane region and missense mutations
primarily affecting aspartate-835 (FLT3-D835) in the carboxy-
terminal receptor tyrosine kinase domain.6 The more common
FLT3-ITD have been associated with 3 APL characteristics: high
white blood count (WBC), S-isoform type, and microgranular
morphology.4 Many additional chromosome abnormalities (ACAs)
have been identified of which a minor fraction are recurrent, most
commonly trisomy 8.5 Studies in transgenic mice indicate that
secondary mutations, including FLT3 mutations or those linked to
certain ACAs, are required for the emergence of fully developed
APL after initiation by PML-RAR.1 In addition, evidence in mice
and/or humans suggests that FLT3 mutations and ACAs or
cytogenetically occult gene copy number variations may be
associated with alternative molecular pathways of disease progres-
sion to frank leukemia.7-9
Studies associated with clinical trials using all-trans retinoic
acid (ATRA)/chemotherapy (CT) have investigated whether the
afore-described genetic abnormalities at diagnosis affect the inci-
dence of posttreatment disease progression and relapse. In some
trials, an association has been found between increased relapse risk
and the S-isoform and/or FLT3-ITD.4,10 However, after adjust-
ment for the associated WBCs by multivariate analysis
(WBC 10 000/L being the most consistent indicator of in-
creased relapse risk after ATRA/CT therapy11), the independent
prognostic significance of the S-isoform and/or FLT3-ITD has
most often been lost or marginalized.3,8,10,12-14 Similarly, in some
ATRA/CT trials, ACAs at diagnosis were associated with increased
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relapse risk by univariate but not multivariate analysis.8,10,15 In
protocol C9710, patients analyzed at diagnosis for FLT3 mutations
and ACAs, the only association with reduced disease-free survival
(DFS) was a complex karyotype ( 2 ACAs; X.P. and W.S.,
unpublished data, June 2012).
ATRA/CT therapy usually reduces the presenting APL cell
population by 5 orders of magnitude.16 Such reduction can result
in the emergence of rare leukemic subclones at relapse that are
hierarchically and genetically distinct from the leukemic cell
population at presentation.17,18 Hence, examination of APL cells at
relapse may provide more information than at diagnosis about
molecular aberrations contributory to relapse and also about
variables that may affect prognosis after postrelapse salvage
therapy. In a previous study associated with Intergroup APL trial
INT0129,19 we found that the predominant relapse clone harbored
mutations in the ATRA-targeted ligand binding domain (LBD) of
PML-RAR (PR/LBD) in one-third of ATRA-treated relapse
patients.20,21 Two results were notable in the small mutation-
positive group (n  6): (1) in 4 patients, the predominant mutation-
harboring clone emerged Off-ATRA treatment, suggesting that
PR/LBD has an alternative role to that of passively selecting
mutant ATRA-resistant clones; and (2) the relapse mutation was
detected in a low-level subclone in 1 of 3 patients studied,
indicating that posttreatment selection rather than de novo acquisi-
tion of PR/LBD can occur. An initial objective of this study was
to determine if the aforementioned relationships of PR/LBD
were altered by the changed treatment of intergroup trial C9710,
which included 2 induction/consolidation treatment arms: an
ATRA/CT-arm in which the 2 agent types were administered
differently than in INT0129; and an arsenic trioxide (ATO)–arm, in
which ATO consolidation was added to the ATRA/CT regimen.22
When it became apparent that the incidence and distribution of
PR/LBD on the ATRA/CT-arm were similar to those on
INT0129 (see “PML-RAR LBD mutations: nature and posttreat-
ment clonal emergence”), we additionally queried in the larger
C9710 relapse cohort analyzed for PR/LBD (n  45) how the
other common genetic aberrations in APL, FLT3 mutations, and
ACAs, relate to PR/LBD and to other APL characteristics. The
objective was to determine whether the inter-relationships of these
parameters provide further insights into the undefined mechanisms
of posttreatment disease progression and relapse.
Methods
Protocol C9710 relapse patients and samples
The 45 patients included in this study were derived from the ATRA/CT-arm
of protocol C9710,22 based solely on the availability after consolidation
therapy of a BM and/or peripheral blood sample evaluable for a PR/LBD
mutation at relapse. Up to the cut-off date for sample acquisition (May
2007), 81 of 294 (28%) ATRA/CT-arm patients had relapsed, including
62 of 237 (26%) adults and 19 of 57 (33%) children ( 15 years old).
Sample recovery was: 34 of 62 (55%) for adults, 11 of 19 (58%) for
children, and 45 of 81 (56%) overall. After May 2007, there were
8 additional relapses in 7 adults and 1 child (April 2012), which were not
analyzed. Too few patients from the alternative adult C9710 ATO consolida-
tion arm (ATO-arm) relapsed (n  7) for analysis.22 Relapse signified
clinical relapse; however, 2 patients, who were reclassified after central
review from clinical relapse to nonrelapse were included based on detection
of molecular relapse by quantitative RT-PCR. Subsequently, samples or
data were collected at relapse and diagnosis to assess FLT3-ITD,
FLT3-D835, and ACA; available samples from patients with a PR/LBD
mutation at relapse were also retrospectively tested at diagnosis. All
patients signed consent for correlative laboratory studies according to the
Declaration of Helsinki, and all participating institution’s review boards
approved this study.
The sodium metrizamide-fractionated, low-density mononuclear cells
from all diagnostic samples had  70% blasts/promyelocytes (X.P. and
W.S., unpublished data, June 2012). Relapse samples were assessed by the
PML-RAR transcript level.16 Total cellular RNA and genomic DNA were
extracted as described elsewhere (X.P. and W.S., unpublished data, June
2012).
PML-RARmethods
Conventional RT-PCR to identify PML-RAR isoform type and nested
PCR and DNA sequence analysis to identify mutations in the RAR-region
of PML-RAR were performed as described (1 primer substitution;
supplemental Table 1, available on the Blood Web site; see the Supplemen-
tal Materials link at the top of the online article).16,20 Procedures for
quantitative RT-PCR measurement of PML-RAR transcript levels by
normalization to transcripts for the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) have also been reported.16 A modifica-
tion of the amplification refractory mutational system procedure23 was
developed, using mutation-specific primers, to identify PR/LBD at high
sensitivity (103-104) in diagnostic or prerelapse samples (supplemental
Methods; supplemental Tables 1 and 2; supplemental Figure 1).
Determination of FLT3 mutation status
FLT3-ITD and FLT3-D835 were detected in genomic DNA using the
FLT3 Mutation Assay (InVivoScribe) or in total cellular RNA using
published procedures.24 Quantitative measurement of FLT3-ITD and
FLT3-D835 allele levels relative to total FLT3 alleles used genomic DNA
(X.P. and W.S., unpublished data, June 2012). FLT3 mutation status at
relapse, in which the percentage of APL cells was unknown, is only
reported for samples in which the GAPDH-normalized PML-RAR copy
number was 105 to exclude possible false-negative results.
Cytogenetic methods
Cytogenetic analysis used standard G- or Q-banding techniques. Karyo-
types were designated according to the International System for Cytoge-
netic Nomenclature. ACAs were defined as chromosome changes in
addition to the APL-specific t(15;17)(q22;q21).
Statistical methods
Genetic aberrations were treated as dichotomous variables and were
examined for their relationships to one another and other dichotomous
variables using Fisher exact test. Continuous variables were assessed using
the Satterthwaite test.25 The multiple P values for the many parameters
evaluated by univariate analysis in this study are considered exploratory
and descriptive in nature to indicate the relative strength of the relationship
between variables and not as observed significance levels for hypothesis
testing. Consequently, corrections for multiple testing were not applied, and
we have used the terminology “association not indicated” for P val-
ues  .10 unless there is some other consideration for citation. Multivariate
analysis of the genetic aberrations relative to all parameters was performed
by logistic regression, but stable results were only achieved at diagnosis
related to small sample size. The following parameters were assessed: age,
sex, presenting WBC count (pWBC), M3 versus M3 variant cytology, time
to relapse (TTR; days from complete remission), relapse On- or Off-ATRA,
postrelapse death, PML-RAR isoform type, and all 3 alternative genetic
aberrations. The pWBC was assessed for P values  .05 as high (pWB-
Chigh) for pWBCs 10 000/L or as low (pWBClow) for pWBCs 5000/L
in overall analyses or as  or  the median pWBC (6800/L), respec-
tively, for smaller ATRA-stratified subsets.
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Results
Relapse study group parameters
Table 1 summarizes the clinicopathologic parameters assessed for a
relationship to the 4 tested genetic aberrations (individual data in
supplemental Table 3). Notably, the study group included 11 pediatric
cases ( 15 years old) not included in reports of adult C9710 cases
(X.P. and W.S., unpublished data, June 2012).22 Compared with all
294 ATRA/CT-arm patients, the 45-patient relapse cohort had an
increased proportion of patients with a high relapse-risk pWBC
( 10 000/L), 41% versus 24%. This is consistent with lower DFS in
adults with high pWBCs on the ATRA/CT-arm (X.P. and W.S.,
unpublished data, June 2012). Similarly, the proportion of S-isoform
cases was increased in the 45-patient set, 64% versus 39% overall. This
is also consistent with trends on the ATRA/CT-arm toward an increased
relapse incidence and reduced DFS in S-isoform compared with
L-isoform patients (X.P. and W.S., unpublished data, June 2012).
In contrast, there was no increase in the incidence of cases with
the hypogranular M3 variant cytology in relapse (13%) compared
with overall ATRA/CT patients (17%; X.P. and W.S., unpublished data,
June 2012).
PML-RAR LBD mutations: nature and posttreatment clonal
emergence
At relapse, 19 amino acid-altering nucleotide base changes in the
RAR region of PML-RAR (all in the LBD) were identified in
18 of 45 (40%) patients (Figure 1). Seventeen PR/LBD were
single base substitutions (missense) and 2 were small deletions that
maintained the open reading frame. One patient had 2 missense
mutations (L224P and R276Q), which were shown to be in separate
clones by recombinant isolation and sequence analysis (not shown).
The mutations were localized to 3 subregions (zones) of the LBD,
which are primarily involved in ATRA-dependent transcriptional
regulatory activity.26,27 The intervening LBD areas involved in
heterodimer formation with RXR were free of mutations. The
predominance of mutations in zone I, which forms the ATRA
binding pocket and central binding cleft for transcriptional cofac-
tors, is consistent with previous findings.28 However, the greater
number of mutations in zone III (n  6) than zone II (n  1) is
contrary to previous reports of PR/LBD in both relapse patients
and ATRA-resistance–selected APL cell lines (additional mutation
information in supplemental Table 4).28,29
The PR/LBD affected 50% of PML-RAR transcripts in
all cases and were the only forms detectable by allele-specific
sequence analysis in 16 of 18 cases (individual case data in
supplemental Table 5). These observations applied whether relapse
occurred On-ATRA– or Off-ATRA–containing therapy. Con-
versely, no mutant allele was detectable by this method (sensitiv-
ity  101) at diagnosis in 16 cases tested. Using a higher
sensitivity mutation-specific primer assay (sensitivity 103-104), a
subclone harboring the relapse mutation was detected at diagnosis
in 2 of 7 cases tested (supplemental Figures 2 and 3; supplemental
Table 5). In the 2 mutation-positive cases, it was further determined
that the mutation-harboring subclone emerged as a major clone
only as relapse neared (Table 2; supplemental Figure 3). In case
27 (relapse On-ATRA), synchronous emergence of the mutant
subclone occurred in the BM and peripheral blood. In case
31 (relapse Off-ATRA), a slowly expanding wild-type PML-RAR
clone predominated at molecular relapse in the BM, whereas a
later-emerging, more rapidly expanding clone harboring the PR/
LBD mutation detected at diagnosis was highly penetrant ( 90%)
in peripheral blood. These observations confirm a previous single
case report21 that the predominant PR/LBD mutant clone at
relapse is derived by selection of a preexisting mutant subclone
rather than by posttreatment acquisition in some cases (cannot
exclude additional cases with mutant subclones at 103-104 fre-
quency among up to 1012 APL cells at disease presentation) and suggest
that a variable relationship of PR/LBD mutation-harboring subclones
to ATRA selection pressure is operative, leading to relapse On- or
Off-ATRA treatment (see “Discussion”).
Table 1. Relapse study group parameters (n  45)
Parameter No. (%) or median (range)
Sex Male, 25 (56%); female, 20 (44%)
Age, y 32 (1-68)*
WBC, 	 103/L 6.8 (0.6-143)†
APL cytologic type‡ M3, 37 (82%); M3 variant, 6 (13%)
PML-RAR type S-isoform, 29 (64%); L-isoform, 16 (36%)
Days to relapse 528 (134-1431)
ATRA status at relapse§ On-ATRA, 20 (44%); Off-ATRA, 25 (56%)
Postrelapse death Alive, 30 (67%); dead, 15 (33%)
For complete data on all 45 relapse patients, see supplemental Table 3.
*Distribution:  15 years, 11; 15-60 years, 28; and  60 years, 6.
†Distribution:  5 	 103/L, 43%; 5-10	103/L, 16%;  10	103/L, 41%.
‡French-American-British subclassification	103; 2 patients could not be subclas-
sified.
§On-ATRA, relapse within 30 days of last ATRA dose; Off-ATRA, relapse
 30 days after last ATRA dose (actual range, 86-966 days).
Median follow-up of surviving patients  71 months.
Figure 1. Mutation sites in the ligand binding domain of PML-RAR after relapse on protocol C9710 (ATRA/CT-arm). Œ represents site of 17 missense mutations; and
‚, site of 2 deletion (
) mutations. 
207-208, 
K207Y208/T207 indicates deletion of lysine and tyrosine corresponding to amino acids 207 and 208 of normal RAR with
maintenance of the normal downstream reading frame beginning with RAR threonine 209, now 207; similarly, 
412-414, 
E412M413L414/E4153E412.
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FLT3 mutations: minor changes from diagnosis to relapse
FLT3-ITD were present in 46% and 37% of cases and FLT3-
D835 in 22% and 12% of cases, respectively, at diagnosis and
relapse (n  41; 4 patients different at the 2 time points). Among
37 patients with paired pretreatment and relapse analyses, the
corresponding incidences were 43% and 41% (FLT3-ITD) and
22% and 14% (FLT3-D835; Table 3). In the paired subset,
changes in mutation status occurred from diagnosis to relapse in
5 of 18 patients with FLT3-ITD and in 5 of 9 patients with
FLT3-D835, yielding a net loss of 1 and 3 mutant cases,
respectively. Loss of FLT3 mutations often occurred in cases with a
low level of the mutation-harboring clone at diagnosis. There were
no differences in FLT3-ITD mutation status or change related to
relapse On-ATRA– or Off-ATRA–containing therapy; 4 of
5 FLT3-D835 cases relapsed On-ATRA (Figure 2). Quantitative
results available in a subset of patients indicated that the level of the
mutant allele relative to total FLT3 allele was always  50% and
that differences were modest in 5 cases with paired FLT3-ITD
determinations at diagnosis and relapse.
Karyotype abnormalities: ACA nonselectively increased at
relapse
ACAs were present in 10 of 39 patients at diagnosis (26%) and in
13 of 21 patients at relapse (62%). All 21 relapse cases were also
analyzed at diagnosis, and 6 (29%) had ACAs (Table 4). All
6 ACAs at diagnosis were retained at relapse, and the only case
with  100% ACA in t(15;17)–positive metaphase cells at diagno-
sis acquired 100% status at relapse. Two ACA-positive cases and
7 ACA-negative cases at diagnosis had newly present ACA at
relapse. Single ACAs were newly present in the predominant
relapse clone in 7 patients, whereas in 2 patients with 2 ACA the
clonal penetration was mixed or uncertain.
Table 4 summarizes all ACA observed in the study (complete
karyotypic data in supplemental Tables 5 and 6). Chromosome
8 abnormalities were most frequent. Trisomy 8 was present at
diagnosis in 4 of 39 (10%) and at relapse in 4 of 21 (19%) cases
analyzed. All 3 patients with trisomy 8 at diagnosis, who were
analyzed at relapse, retained the 8, 2 as the sole ACA and 1 in a
complex karyotype. In 1 case each, trisomy 8 or i(8)(q10) was
newly present at relapse, bringing the total relapse cases with 8q
duplication to 5 of 21 (24%). The second most frequent ACA was
ider(17q), which was present at diagnosis in 2 of 39 (5%) and at
relapse in 2 of 21 (10%) cases analyzed; the latter included
1 retained from diagnosis and 1 newly present at relapse in a
complex karyotype with trisomy 8. Balanced translocations in-
creased from diagnosis to relapse both in incidence, 8% (3/39) to
29% (6/21), and as a fraction of all ACA, 30% (3 of 10) to 46%
(6 of 13). A t(4;5) occurred in 2 cases with a common breakpoint in
5q31; the chromosome 4 breakpoints affected neighboring bands,
4q21 and 4q23. All other structural chromosome changes were
nonrecurrent. A complex karyotype was present in 1 of 39 (3%)
cases at diagnosis and 3 of 21 (14%) patients at relapse.
Association analysis of genetic aberrations at diagnosis
Table 5 summarizes the test parameters for which an indication of
association was identified by univariate or multivariate analysis
(supplemental Tables 7 and 8 for all data). By univariate analysis,
FLT3-ITD were strongly associated with a pWBChigh and with an
increased incidence of the S-isoform; ACAs were associated with a
longer TTR. By multivariate analysis, all 3 aberrations had a
different set of relationships, except for weaker associations of
FLT3-ITD with the S-isoform and pWBChigh. FLT3-D835 were
also associated with pWBChigh, an association also found in overall
C9710 patients (X.P. and W.S., manuscript submitted, June 2012)
Table 2. Serial monitoring of 2 patients with detectable PR/LBD mutations at diagnosis by high-sensitivity mutation-specific primer assay
PR/LBD mutation level PML-RAR transcript level*
Marrow Blood Marrow Blood
Patient 27 (R276Q)†
Diagnosis  1/1000  1/800‡ 400 40
Postinduction  1/1000  1/300‡ 1 NA
Postconsolidation  1/1000  1/1000 0.003 0.007
Maintenance 4 months  1/70  1/70  0.001  0.001
Maintenance 9 months  1/10 NA 0.01 NA
Relapse/postmaintenance 1 month  90/100‡  90/100‡ 1000 10
Patient 31 (K238E)†
Diagnosis  1/900‡  1/300‡ 900 600
Postinduction  1/900‡  1/1000 3 1
Postconsolidation  1/1000  1/800 0.007 NA
Postmaintenance  1/1000  1/1000  0.001  0.001
Postmaintenance 8 months  1/1000  1/1000 0.008  0.001
Postmaintenance 20 months  1/1000  1/1000‡ 0.9  0.001
Relapse/postmaintenance 28 months  1/700‡  90/100‡ 200 4
See supplemental Methods and supplemental Figure 3 for serially plotted data. The “” symbol indicates mutation not detected at indicated assay sensitivity limit.
NA indicates not available.
*Numbers indicate the number of PML-RAR transcript copies per 105 copies of GAPDH.
†Maintenance therapy for 1 year was single-agent ATRA in patient 27 and ATRA plus 6-mercaptopurine and methotrexate in patient 31.
‡Detectable at the indicated level (eg, 1 mutant copy detected per 800 total PML-RAR copies).
Table 3. Changes in FLT3 mutation status from diagnosis (D) to relapse (R) in 37 patients with paired sample analysis
FLT3 mutation Stable negative Loss D3 R Gain D3 R Stable positive Net change Percent positive
Diagnosis Relapse
FLT3-ITD 19 3 2 13 1 43 41
FLT3-D835 28 4 1 4 3 22 14
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and also showed a weak trend toward association with the
S-isoform. FLT3-ITD and FLT3-D835 were reciprocally nega-
tively associated, and ACAs were associated with older age.
Association analysis of genetic aberrations at relapse
Univariate association analysis at relapse was made in a 41-patient
subset evaluable for both PR/LBD and FLT3 mutations (positive
results summarized in Table 6; all results in supplemental Table 9).
PR/LBD were associated with pWBClow and tended to occur more
frequently if relapse occurred On-ATRA treatment. Conversely, FLT3-
ITD were associated with a pWBChigh and the S-isoform. FLT3-ITD
were also inversely (negatively) associated with ACAs. The small
number of FLT3-D835 (n 5) impeded analysis, although the TTR in
patients with FLT3-D835was reduced; correspondingly, 4 of 5 patients
Figure 2. Qualitative and quantitative variations in FLT3 mutations from diagnosis to relapse: majority stable; loss of minor subclones; unbiased relapse
distribution of FLT3-ITDOn-ATRA/Off-ATRA; possible On-ATRA relapse bias of FLT3-D835; and coincidence of FLT3-ITD and PR/LBD after relapse On-ATRA.
(A) FLT3-ITD mutation-positive cases at diagnosis and/or at relapse. (B) FLT3-D835 mutation-positive cases at diagnosis and/or at relapse. White represents mutation not
detected; gray, mutation detected; black, no result available; and darker gray, coincident PR/LBD mutation. Numbers indicate the percentage of mutant FLT3 allele relative to
total FLT3 allele; nonbold indicates minor subclone ( 15%). Four cases each (3 in the same case; 1 each in different cases; supplemental Table 6) were not assayed at
diagnosis for FLT3-ITD and/or FLT3-D835 mutations and, additionally, did not have detectable mutations at relapse; thus, these cases are not represented in the figure panels.
Table 4. Chromosomal abnormalities in addition to t(15;17) (ACAs) identified at diagnosis and relapse
Patient no. ACA at diagnosis* ACA at relapse†
5 None t(3;11)(q28;q23), 10/19‡
6 None t(3;12)(p12;q24.3), 20/20
15 None t(4;5)(q21;q31), 4/4
9 None add(6)(q21), 2/2
12 None 8, 19/19
4 None i(8)(q10), 20/20
10 None Clone 1: add(22)(p11.2), 8/16; clone 2: idem,add(7)(q33), 2/16
1 t(4;5)(q23;q31), 11/11‡§ t(4;5)(q23;q31); del(20)(q11.2q13.3), 3/3
7 8, 19/19 8, 9/9
8 8, 3/3 8; ?del(4)(q25),der(15)t(15;17)(q22;q21),13,
der(?16)t(13;16)(q12;q11), ider(17)(q10)t(15;17)(q22;q21), 1/1
20 8, 11/15 8, 20/20
3 t(10;11)(q11.2;p11.2), 19/19§ t(10;11)(q11.2;p11.2), 19/19
19 der(15),ider(17)(q10) t(15;17)(q22;q21), 16/16 der(15),ider(17)(q10) t(15;17)(q22;q21), 3/3
35 add(8)(p23), 20/20 Not available
45 8, 20/20 Not available
43 add(12)(p13), 19/19 Not available
40 Clone 1: t(14;22)(p11.2;q11.2), 11/13; Clone 2: idem,ider(17)(q10) t(15;17)(q22;q21),
2/13
Not available
*Results from 39 cases analyzed at diagnosis; see supplemental Table 6 for complete karyotype information.
†Results from 21 cases analyzed at relapse; see supplemental Table 5 for complete karyotype results.
‡Number of metaphase cells with ACA (numerator); total number of t(15;17)–positive metaphase cells (denominator); applies to all fractions in columns.
§These translocations cannot represent constitutional rearrangements because normal karyotypes were also present.
2102 GALLAGHER et al BLOOD, 6 SEPTEMBER 2012  VOLUME 120, NUMBER 10
For personal use only.on August 19, 2015. by guest  www.bloodjournal.orgFrom 
with FLT3-D835 relapsed On-ATRA. ACAs in a 21-patient subset
were associated with the absence of FLT3-ITD and increased post-
relapse death and with a trend toward association with the L-isoform.
Multivariate analysis did not yield stable results.
ATRA treatment status at relapse impacts genetic aberration
associations
We assessed the potential effect of ATRA treatment status at relapse
because defects in ATRA-targeted molecular pathways might be
interactive with differences in intrinsic disease characteristics
and/or the genetic aberrations studied. Remarkably, virtually all of
the associations noted in the overall analysis at relapse (Table 6)
were restricted to relapse Off-ATRA: PR/LBD with pWBClow;
FLT3-ITD with pWBChigh, S-isoform and ACA (negatively; Table
7; details in supplemental Table 10). Exceptionally, FLT3-ITD
remained weakly associated with the S-isoform after relapse
On-ATRA, related to the 100% co-occurrence of these 2 parame-
ters. Although case numbers were very small (n  12), ACAs were
associated with pWBClow, the L-isoform and FLT3-ITD (recipro-
cally). FLT3-D835 were too few for analysis (n  5). This
analysis also revealed a reciprocal negative association of FLT3-
ITD and PR/LBD after relapse Off-ATRA.
We performed an alternative, secondary analysis in the patient
subsets positive for FLT3-ITD and PR/LBD using relapse On-
or Off-ATRA as the variable; and, notably, this revealed a positive
association of these 2 mutations in the On-ATRA relapse set:
among patients with FLT3-ITD, 5 of 6 who relapsed On-ATRA
versus 0 of 9 who relapsed Off-ATRA had coincident PR/LBD
(P  .002; Figure 2A; supplemental Table 11). Similarly, we noted
that all 5 cytogenetically analyzed patients with PR/LBD, who
Table 5. Associations at diagnosis of patients with FLT3 mutations or ACAs by univariate and multivariate analyses
Test parameter
FLT3-ITD mutation FLT3-D835 mutation ACA
Descriptor Univariate* Multivariate† Descriptor Univariate* Multivariate† Descriptor Univariate‡ Multivariate§
Age ANI ANI ANI ANI Older ANI .05
Presenting WBC High .002 .07 High ANI .02 — ANI ANI
Time to relapse ANI ANI ANI ANI Longer .03 ANI
PML-RAR type 1 S-isoform incidence  .001 .04 1 S-isoform incidence ANI .10 — ANI ANI
FLT3-ITD — — — Negative associaton ANI .01 — ANI ANI
FLT3-D835 Negative association ANI .06 — — — — ANI NE
Data for all parameters are listed in “Statistical methods” by univariate and multivariate analysis in supplemental Tables 7 and 8. Descriptor indicates the nature of the
association of the test parameter with the aberration in the heading.
ANI indicates association not indicated; —, not applicable; and NE, not evaluable.
*Univariate analysis of FLT3 mutations had a sample size of n  41, which differed by 1 case each for the FLT3-ITD and FLT3-D835 sets (see supplemental Table 6).
†Multivariate analysis of FLT3 mutations had a sample size of n  39.
‡Univariate analysis of ACA had a sample size of n  39.
§Multivariate analysis of ACA had a sample size of n  35.
Table 6. Associations at relapse of patients with PR/LBD and FLT3 mutations (n  41*) or ACAs (n  21) by univariate analysis
Test parameter
PR/LBD mutations
(18 vs 23*)
FLT3-ITD mutations
(15 vs 26*)
FLT3-D835 mutations
(5 vs 36*) ACA (13 vs 8*)
Descriptor P Descriptor P Descriptor P Descriptor P
Presenting WBCs Low .03 High .006 — ANI — ANI
Time to relapse — ANI ANI ANI Shorter  .001 — ANI
Relapse On-ATRA† Increased incidence .06 — ANI — .15‡ — ANI
Postrelapse death — ANI — ANI — ANI Increased Incidence .05
PML-RAR type — ANI 1 S-isoform incidence  .001 — ANI 1 L-isoform incidence .07
FLT3-ITD — ANI — — — ANI Negative association .003
ACA — ANI Negative association .003 — ANI — ANI
Detailed data for all parameters are listed in “Statistical methods” and in supplemental Table 9. Descriptor indicates the nature of the association of the test parameter with
the aberration in the heading.
— indicates not applicable; and ANI, association not indicated.
*Number positive vs number negative.
†Relapse On-ATRA, relapse within 30 days of last dose of ATRA.
‡Four of 5 patients (80%) with FLT3-D835 versus 14 of 36 patients (39%) without FLT3-D835 relapsed On-ATRA (P  0.15).
Table 7. Associations of PR/LBD and FLT3-ITD mutations and ACAs after relapse On-ATRA or Off-ATRA therapy
Test parameter
PR/LBD mutations FLT3-ITD mutations ACA
Descriptor
On-ATRA
(11 vs 7)
Off-ATRA
(7 vs 16) Descriptor
On-ATRA
(6 vs 12)
Off-ATRA
(9 vs 14) Descriptor
Off-ATRA
(9 vs 3)
Presenting WBCs* Low ANI .001 High ANI  .001 Low .02
PML-RAR type — ANI ANI 1 S-isoform incidence .05 .002 1 L-isoform incidence .05
PR/LBD — — — Negative association ANI .02 — ANI
FLT3-ITD Negative association ANI .02 — — — Negative association .005
ACA — ANI ANI Negative association ANI .005 — —
FLT3-D835 mutations and ACAs after relapse. On-ATRA too few for analysis. Detailed data for all parameters are listed in “Statistical methods” and supplemental Table 10.
— indicates not applicable; and ANI, association not indicated.
*WBC high or low P values were calculated from above or below the median WBC (6800/L).
ATRA IMPACTS MUTATION ASSOCIATIONS IN RELAPSE APL 2103BLOOD, 6 SEPTEMBER 2012  VOLUME 120, NUMBER 10
For personal use only.on August 19, 2015. by guest  www.bloodjournal.orgFrom 
relapsed Off-ATRA had coincident ACAs (Figure 3). Although
PR/LBD and ACAs were not associated in the overall or
On-ATRA/Off-ATRA relapse analyses (Tables 6 and 7), among
patients with PR/LBD, 4 of 6 Off-ATRA relapse versus 1 of
11 On-ATRA relapse patients had ACAs at diagnosis (P  .03;
Figure 3). These observations, as well as the common association
of PR/LBD and ACAs with pWBClow and FLT3-ITD (nega-
tively), suggest a nonreciprocal association of PR/LBD with
ACA at relapse Off-ATRA.
A summary of the inter-parameter associations described above
at diagnosis and relapse is presented in Table 8, and data for all
study parameters related to each genetic aberration are depicted on
an individual case basis in supplemental Figure 4. We acknowledge
that the assigned associations are based on small case numbers and
that they must be considered provisional.
TTR assessments
TTR can be an indicator of the intrinsic malignant properties of
individual leukemias. Thus, we examined relations between TTR
and specific PR/LBD and/or ACAs. In the patient subset,
including all PR/LBD and/or ACA (n  24), the TTRs stratified
into 2 groups: 134-546 days (n  13) or 644-1431 days (n  11),
corresponding to relapse On-ATRA or Off-ATRA (Table 9). The
TTRs were representative of the amount of ATRA administered up
to the completion of maintenance with the exception of patient
1, who relapsed nearly 2 years after completing ATRA-containing
consolidation. Several points seem noteworthy. First, the 3 shortest
TTR (134-218 days) occurred in patients with a PR/LBD in zone
III (Y208N, R217Hx2; Figure 1). Second, the 5 patients with the
shortest TTRs (134-265 days) were pediatric cases (ages 1-11 years). Of
note, the Y208N mutation in a 1-year-old (patient 14) was not detectable
at diagnosis with 104 sensitivity (supplemental Figure 2), excluding
the preexistence of this mutation as a cause of early neonatal relapse.
Third, although almost all zone I mutations occurred during or within
6 months of finishing maintenance, zone III mutations occurred either
soon after finishing consolidation or after prolonged follow-up. Fourth, a
higher proportion of ACAs occurred in the long/Off-ATRA TTR group
(9/9 vs 4/7; P .06), including 4/5 8/i (8q), 2/2 ider (17q), 4/5 balanced
translocations, and 2/3 complex karyotypes. There was, however, no
apparent difference in the proportion of patients with newly present
ACA who experienced short/On-ATRA (3/4) or long/Off-ATRA (6/9)
times to relapse. Finally, the co-occurrence of FLT3 mutations with
either PR/LBD and/or ACA was confined to relatively short-term
relapses On-ATRA.
Postrelapse survival assessments
At a median follow-up of 71 months among surviving patients
(April 2012), 15 of 45 patients (33%) had died and 2 were lost to
follow-up. Of 28 surviving patients with postrelapse follow-up
data, all had longer follow-up time (range, 371-3564 days) than the
median time to death in 14 nonsurvivors (368 days; Table 10). In
this dataset, ACA at relapse was the only genetic aberration
associated with reduced postrelapse survival (P  .05), consistent
with the overall case analysis based on postrelapse death (Table 6).
However, the data were insufficient to assess whether any particu-
lar ACA or type of ACA affected postrelapse survival. PR/LBD
data were also limited, but, notably, 3 of 4 mutations affecting
G289 and both deletion mutations occurred in and constituted 5 of
6 PR/LBD in nonsurvivors. FLT3-ITD occurred 2 times more
often in survivors than nonsurvivors (46% vs 21%), and, although
not significant, this observation makes it improbable that FLT3-
ITD would be associated with reduced postrelapse survival in a
larger sample.
Discussion
Our prestudy hypothesis was that the change in therapy on trial
C9710 vis-a`-vis the previous intergroup trial INT0129 would
reduce the incidence of relapse with clones harboring PR/LBD.
This was based, in part, on a report that concurrent (C9710) rather
than sequential (INT0129) administration of ATRA and CT reduces
the incidence of relapse22,30 and on indications of clinical synergy
of ATO with ATRA.31 After release of C9710 treatment-arm
outcome data, it became apparent that the addition of ATO to
ATRA/CT must have been highly effective in eliminating PR/
LBD-harboring clones because only 7 relapses occurred on the
ATO-arm.22 Conversely, we found no substantive differences
between the ATRA/CT-arm of C9710 and INT0129 regarding the
incidence of PR/LBD at relapse (40% and 33%, respectively) or
distribution of PR/LBD in relapses On-ATRA/Off-ATRA selec-
tion pressure (11/7 and 2/4, respectively; P  .36). We cannot
exclude the possibility, however, that alternative ATRA-CT treat-
ment, which remains standard of care in much of the world,32 might
be more effective in PR/LBD mutant clone reduction.
Table 8. Summary of genetic aberration associations
Overall associations
At diagnosis
FLT3-ITD with S-isoform, pWBChigh
FLT3-D835 with pWBChigh
FLT3-ITD and FLT3-D835 negatively
At relapse
FLT3-ITD with S-isoform, pWBChigh, ACA negatively
ACA with FLT3-ITD negatively, L-isoform, postrelapse death
PR/LBD with pWBClow
ATRA treatment stratified associations at relapse
Relapse On-ATRA
FLT3-ITD with S-isoform, PR/LBD
Relapse Off-ATRA
FLT3-ITD with S-isoform, pWBChigh, ACA and PR/LBD negatively
ACA with pWBClow, L-isoform, FLT3-ITD negatively
PR/LBD with pWBClow, ACA, FLT3-ITD negatively
Figure 3. In patients with PR/LBD, coincident ACA occurred more frequently after relapse Off-ATRA in patients with ACA at diagnosis. White represents ACA
absent; gray, ACA present; darker gray, newly detected ACA at relapse; and black, no cytogenetic analysis.
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A rationale for the involvement of PR/LBD in relapse clone
selection is that PR/LBD-harboring APL cells are resistant to
ATRA-induced differentiation, resulting in their passive selection
because of the elimination of ATRA-sensitive APL cells containing
wild-type PML-RAR.28 Consistent with this notion, the majority
of C9710 cases harboring PR/LBD (61%) relapsed On-ATRA.
Nevertheless, the fraction of PR/LBD–positive patients who
relapsed long after the cessation of ATRA therapy (39%) is notable.
Further, the relapse PR/LBD mutation detected in a low-level
subclone at diagnosis in 2 cases in this study and 1 case in a
previous study21 only emerged late in proximity to relapse. These
observations suggest that PR/LBD may have an active, ATRA-
independent role, as well as an ATRA-dependent passive role, in
relapse clone selection. A potential mechanism by which this might
occur is augmentation of the fundamental self-renewal–promoting
activity of PML-RAR involved in APL initiation and propaga-
tion.33,34 Consistent with this possibility, APL cells expressing
mutant PML-RAR/LBD produced more aggressive leukemias
than those expressing wild-type PML-RAR after transplantation
to secondary recipients in a transgenic mouse model.35 Further
investigations are needed to assess this speculative gain-of-
function activity. Such investigations might further consider whether
this activity is related to the site of mutation in the LBD because
our study suggests that relapse clones harboring mutations in the
amino-proximal portion of the LBD are less tightly linked to ATRA
selection pressure than mutations in the central binding cleft.
Unlike PR/LBD, FLT3-ITD were already prevalent at
diagnosis, did not increase at relapse, and were evenly distributed
Table 9. Relationship of TTR to specific PR/LBD and ACA, age, and FLT3 mutations
Patient no. TTR, days Days of maintenance PR/LBD ACA Age FLT3 mutation
14 134 0 Y208N† None 1§ ITD
32 175 0 R217H† NA 4§ ITD
39 218 107 R217H† NA 11§ —
5 265 118 N t(3;11)‡ 11§ —
10 265 130 N add(22p)‡ add(7q)‡ 3§ D835
22 309 179 
412–414 NA 44 —
30 339 196 I273F NA 43 ITD
9 359 231 G289E add(6)(q21)‡ 35 —
17 363 218 R276Q and L224P† None 65 ITD and D835‡
7 401 279 G289E 8 42 ITD
11 520 365 T285A None 28 —
27 528 365 R276Q NA 32 —
37 546 365 G289R NA 15 —
15 644* 365 R272Q t(4;5)‡ 13§ —
4 655* 365 N i(8)(q10)‡ 31 —
20 657* 365 R276W 8 64 —
12 678* 365 N 8‡ 31 —
8 682* 365 G289R 8 and 3ACA‡ 49 —
40 686* 365 S287W NA 49 —
3 718* 365 N t(10;11) 17 —
1 728* 0 S287L t(4;5),del(20)‡ 64 —
6 874* 365 
207–208† t(3;12)‡ 18 —
19 1057* 365 N ider(17q) 36 —
31 1431* 365 K238E† NA 32 —
— indicates not applicable.
*Relapse Off-ATRA.
†Zone III LBD mutations.
‡Newly detected at relapse.
§Pediatric cases.
Table 10. Relationship of genetic aberrations and recurrent subtype aberrations to postrelapse survival
Parameter Nonsurvivors (n  15) Survivors (n  28) P
Median postrelapse survival, d (range) 368* (6-1104) 1497* (371-3564)  .001*
ACA, % positive 100* (6) 50* (12) .05*
8/i(8q), cases 3 2 —
Balanced translocation, cases 2 3 —
Complex karyotype, cases 1 1 —
PR/LBD mutations, % positive 40 39 NS
Missense mutations, cases 4 11 NS
G289E/R, cases 3* 1* —
R276Q/W, cases 1 2 —
Deletion mutations, cases 2* 0* —
FLT3-ITD mutations, % positive 21* 46* (26) .18
FLT3-D835 mutations, % positive 7 13 (24) NS
Individual case data are detailed in supplemental Table 12. Numbers in brackets indicate the number of cases tested if less than total cases indicated by “n” in the NS
corresponding column heading.
— indicates too few for analysis; and NS, no significant difference.
*Distribution differences of possible interest between nonsurvivors and survivors.
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at relapse On- or Off-ATRA. Further, in patients with paired
quantitative analyses of FLT3-ITD at diagnosis and relapse, there
was no increase in the level of the mutant allele relative to total
FLT3 alleles (ratio  50%). Thus, there was no evidence that FLT3
mutations, considered as single lesions, are contributory to post-
therapy disease progression in contrast to their established role in
disease pathogenesis.1 However, when analyzed in the context of
other study parameters, at least one potential contributory mecha-
nism was revealed related to ATRA treatment status at relapse. All
FLT3-ITD patients who relapsed Off-ATRA lacked PR/LBD,
whereas most FLT3-ITD patients (83%) who relapsed On-ATRA
had a coincident PR/LBD. The latter positive association
suggests an ATRA-dependent complementary interaction between
these mutations. A scenario by which this might occur is that
ATRA-induced reduction of competition with the bulk APL cell
population permits growth of the double-mutant subclone because
of constitutive FLT3-ITD growth stimulatory activity, which
would be further enhanced if PR/LBD have gain-of-function
activity. This mechanism does not necessarily require an increase
in FLT3-ITD kinase activity, possibly a critical consideration,
because FLT3-ITD mutant allele levels did not increase at relapse
in contrast to non-APL AML.36 A clinical consideration is that
patients who relapse with both mutations might selectively benefit
from treatment with FLT3 kinase inhibitors.
Genetic change associated with chromosomal abnormalities has
been implicated as an essential complementary factor in driving
progression of PML-RAR–initiated disease to frank leukemia in
mouse APL models.1,5,37,38 In humans, a similar involvement of
ACA in disease development has been postulated but remains
unsubstantiated,1,39 while clinical trial studies have found no
independent association between ACA at diagnosis and treatment
outcome (X.P. and W.S., manuscript submitted, June 2012).10,14
Our study also suggests that ACA present at diagnosis do not
predispose to posttreatment progression, since there was no
increase in the incidence of ACA at diagnosis in the relapse subset
(26%) compared with overall adult C9710 patients (28%; X.P. and
W.S., unpublished data, June 2012). The most frequent ACA in
APL, trisomy 8/i (8q), which has the most compelling supportive
evidence for a possible linkage to pretreatment disease progres-
sion,9,38 had the same incidence in both the overall and relapse
cohorts (10%). A complex karyotype, which occurred in 9% of
overall C9710 adults at diagnosis and was associated with reduced
DFS (X.P. and W.S., unpublished data, June 2012), was only
present at diagnosis in 1 relapse case (3%), probably because of
chance exclusion from the study cohort. At relapse, exclusive ACA
gains occurred, resulting in a 2-fold increased incidence of ACA
(29% to 62%). Proportionate increases occurred in trisomy 8/i (8q)
(10%-24%) and ider17q (5%-10%), the second most frequent ACA
in APL.40 These increases seem consistent with hypotheses that
gene dose effects, including increased oncogene activity,9,38 might
contribute to posttreatment progression in these patients, but the
proportionality argues against a posttreatment-specific effect. Bal-
anced translocations also increased in incidence (8%-29%), which
included a recurrent t(4;5) with a common 5q31 and neighboring
4q23 and 4q21 breaksites. Although 5q31 has rarely been reported
in translocations in APL, rearrangements affecting 4q21, including
complex insertion/rearrangements with PML-RAR, have been
recurrently reported.5,41,42 More generally, several structural chro-
mosome changes seem of potential functional interest: they were
predominantly newly present at relapse; most differ from ACAs
commonly reported at diagnosis43 and/or are contiguous to candi-
date leukemia/cancer genes (supplemental Table 13). Further study
is required to determine whether any of the heterogeneous ACAs
have clinically relevant functional significance or whether they
represent adventitious abnormalities. If functionally relevant, the
molecular pathways involved seem likely to be disparate, although
linkage to a shared central network process(es) cannot be
discounted.9,38
Despite their heterogeneity, ACAs were associated with an APL
phenotype characterized by pWBClow and L-isoform, if relapse
occurred Off-ATRA. This phenotype was shared by patients who
relapsed Off-ATRA with a PR/LBD, all whom had coincident
ACA at relapse. Further, there was a propensity for PR/LBD to
emerge in patients who already had ACAs at diagnosis. This
suggests that the association may reflect inherently increased
genetic instability in this APL phenotype. As such, the ACA and/or
PR/LBD might be coincidental to the relapse process. However,
such genetic instability might also generate aberrations that ac-
tively participate in the process, which seems more consistent with
the otherwise unexplained frequency and clonal penetration of
PR/LBD in relapse clones that emerge off of ATRA selection
pressure. In this scenario, the augmented self-renewal activity of
mutant PML-RAR, as discussed above, might, for example,
complement increased oncogene-stimulated clonal growth in a
patient with trisomy 8. Another common feature of the shared
ACA-PR/LBD phenotype is the negative association with
FLT3-ITD, which is strongly associated with the opposing APL
phenotype characterized by pWBChigh and S-isoform. This could
indicate that FLT3-ITD are associated with an alternative mecha-
nism of posttreatment progression after relapse Off-ATRA, al-
though this study provides no evidence of a possible mechanism.
Notably, the above dichotomized associations are not apparent after
relapse On-ATRA (Table 7), suggesting that ATRA-specific resis-
tance mechanisms are involved and short-circuit distinct phenotype-
linked pathways of disease progression that are manifest after
relapse Off-ATRA. We acknowledge that the proposed interactions
are speculative and might have alternative explanations, including
involvement of an occult mutation(s) unrelated to phenotypic
characteristics, as recently reported in a murine APL model,39 or
involvement of other unrecognized abnormalities that could affect
the timing of relapse independent of ATRA treatment.
Finally, we additionally assessed the relationship of the genetic
aberrations to clinical outcome irrespective of potential functional
involvement. This was assessed by the incidence of postrelapse
death in all 45 relapse patients and by postrelapse survival in
35 patients with sufficient follow-up to provide an indication of
response to salvage therapy. No case-specific information is
available about salvage therapy in C9710 patients after first relapse,
but in all likelihood the great majority received ATO because this is
standard of care.44 Of the 4 genetic aberrations, only the presence
of ACA at relapse was associated with reduced postrelapse
outcome. However, particular ACA either showed no apparent
association or because of small numbers and heterogeneity could
not be evaluated for an association with postrelapse survival. A
subset of patients with PR/LBD had reduced postrelapse sur-
vival: among 6 nonsurvivors with PR/LBD, 3 had missense
mutations of G289 and 2 had deletion mutations. In a previous
study, both patients with a deletion in the PR/LBD were also
nonsurvivors.45 In addition, 4 pediatric/juvenile cases with muta-
tions affecting Y208 or R217 in amino-proximal LBD may have
had a more aggressive or less treatment-sensitive form of APL
because 3 had the shortest TTR and the fourth was a nonsurvivor.
There was no indication that FLT3-ITD or FLT3/D835 at relapse
had an adverse impact on postrelapse outcome, and 4 of 5 patients
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evaluable for outcome who relapsed On-ATRA with dual FLT3-
ITD and PR/LBD mutations were long-term survivors. From
these findings, we suggest that the collection of further genetic
aberration data from first-relapse APL patients would probably
identify minor patient subsets that may benefit from nonstandard
postrelapse therapy and that such data may be particularly informa-
tive in patients who are not responding well to salvage therapy.
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